- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
No frown lines as onabotulinumtoxinA turns 10
April 15 marked the 10-year anniversary of FDA approval of onabotulinumtoxinA (Botox Cosmetic, Allergan) to help improve the look of moderate to severe frown lines between the eyebrows in patients aged 18 to 65 years.
Irvine, CA-April 15 marked the 10-year anniversary of FDA approval of onabotulinumtoxinA (Botox Cosmetic, Allergan) to help improve the look of moderate to severe frown lines between the eyebrows in patients aged 18 to 65 years.
OnabotulinumtoxinA was first approved by the FDA in 1989 for the treatment of strabismus and blepharospasm, making it the first botulinum toxin type A product approved in the world. Since its first approval, onabotulinumtoxinA has been recognized by regulatory authorities worldwide as an effective treatment for 25 different indications in approximately 85 countries.
Globally, about 30 million vials of onabotulinumtoxinA have been distributed, according to Allergan.
For more articles in this issue of Ophthalmology Times eReport, click here.
